The overall market size is expected to grow by 8X during the same period, supported by expanding treatment eligibility, increasing public reimbursement coverage, and growing clinical evidence for cardiovascular risk reduction benefits
In the same timeframe I also started collecting data, so getting my book ready
Rival incretin-based therapies from Novo Nordisk, including semaglutide-based blockbusters Ozempic and Wegovy, continue to anchor the market, although Eli Lilly has been taking the edge with its tirzepatide products Mounjaro and Zepbound
Your prescriber can reach Quartz's PA line directly for submission details
During the procedure, your doctor looks for polyps small growths in the colon that can sometimes turn into cancer and removes them before they become a problem
Therefore, the decrease in the differentiation of L-cells may be due to the reduction in stem cell proliferative capacity induced by chronic hyperglycemia [31]